🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

KMC Speciality Hospitals (India) Limited KMCSHIL NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.kauveryhospital.com
Company Profile ↓
₹150.05
+5.69% 1Y
Mkt Cap₹2,447.09 Cr
P/E43.62
P/B12.07
52W High₹183.22
52W Low₹132.80
Book Value₹12.95
EPS (TTM)₹3.44

Company Overview

KMC Speciality Hospitals (India) Limited provides medical and healthcare services in India. The company offers healthcare services in the areas of anesthesiology, arthroscopy, breast clinic, cardiology, critical care, dermatology, dental maxillofacial, diabetology, emergency and urgent care, endocrinology, family clinic, fertility centre, general surgery, general medicine, geriatrics, gastroenterology, heart and lung transplant, interventional radiology, infectious diseases, laboratory services, lung centre, liver disease, neurology, and neurosurgery; and nephrology and urology science, as well as ENT, head, and neck surgery; and kidney, liver, and bone marrow transplant. It also provides healthcare services in the areas of ophthalmology, obstetrics and gynecology, orthopaedics, oncology, paediatrics and neonatology, plastic surgery, psychiatry, pulmonology, rheumatology, spine surgery, transfusion medicine, sports medicine, and vascular surgery. The company was formerly known as Seahorse Hospital Limited and changed its name to KMC Speciality Hospitals (India) Limited in October 2008. KMC Speciality Hospitals (India) Limited was incorporated in 1982 and is based in Trichy, India. KMC Speciality Hospitals (India) Limited is a subsidiary of Sri Kauvery Medical Care (India) Limited.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 22.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 22.9%.

Consistent Profit Growth

Net profit has compounded at 20.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 25.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 16.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.40.

Recent Developments

  • Mar 2026 Revenue of ₹305.77 Cr (+32.0% YoY); net profit ₹46.73 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +37.9%, earnings +121.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 25.4%, profit CAGR 20.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:25.45%
1 Year:37.90%

Compounded Profit Growth

5 Years:20.53%
1 Year:121.70%

Stock Price Performance

1 Year:+5.69%
6 Months:-
3 Months:-
1 Month:-0.14%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 34% of range
₹132.80 ₹183.22
Trend Signals
  • RSI (14)42.86 · Neutral
Price Performance
1M-0.14%
1Y+5.69%
Valuation vs Sector

P/E of 43.62 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 22.2%.
  • Healthy ROCE of 22.9%.
  • Compounding revenue at 25.4% over 5 years.
  • Profit CAGR of 20.5% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
43.62
Industry PE
36.43
Forward P/E est.
21.81
PEG Ratio
-
Book Value
₹12.95
Price to Book
12.07
P/S
7.70
EV/EBITDA
25.57
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
25.45%
Profit 5Y
20.53%
Revenue (YoY)
37.90%
Earnings (YoY)
121.70%

Profitability & Returns

ROCE
22.89%
ROE
22.21%
ROA
14.07%
Profit Margin
16.85%
Op Margin
24.66%
Gross Margin
64.60%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹3.44

Balance Sheet & Liquidity

Debt/Equity
0.40
Quick Ratio
1.81
Current Ratio
1.90
Debt
₹83.68 Cr
Total Assets
₹332.12 Cr
Current Assets
₹81.21 Cr
Working Capital
₹38.54 Cr

Ownership

Promoter Holding
77.49%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹2,447.09 Cr
Total Revenue (TTM)
₹330.99 Cr
EBITDA
₹100.40 Cr
Free Cash Flow
₹62.46 Cr
Operating Cash Flow
₹79.10 Cr
Shares Outstanding
₹16.31 Cr
Gross Margin
64.60%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KMCSHIL KMC Speciality Hospitals (India) Limited NSEPHARMA 150.05 43.62 ₹2,447.09 Cr 0.00% 22.89% 22.21% 25.45% 20.53%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 60.93 Cr66.55 Cr74.90 Cr82.06 Cr82.25 Cr
Cost of Revenue 9.49 Cr10.36 Cr11.04 Cr11.45 Cr12.17 Cr
Gross Profit 51.45 Cr56.19 Cr63.87 Cr70.61 Cr70.09 Cr
Operating Expenses 41.10 Cr44.82 Cr48.33 Cr51.20 Cr50.16 Cr
Operating Income 10.34 Cr11.37 Cr15.54 Cr19.42 Cr19.93 Cr
EBITDA 16.21 Cr17.25 Cr22.09 Cr25.88 Cr27.78 Cr
Interest Expense 2.31 Cr2.16 Cr2.05 Cr2.07 Cr2.03 Cr
Pretax Income 8.82 Cr10.01 Cr14.74 Cr18.48 Cr19.80 Cr
Tax Provision 4.30 Cr2.47 Cr3.90 Cr4.75 Cr5.17 Cr
Net Income 4.52 Cr7.54 Cr10.84 Cr13.73 Cr14.63 Cr
Diluted EPS -----

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -154.89 Cr175.42 Cr231.60 Cr305.77 Cr
Cost of Revenue -22.97 Cr24.42 Cr33.68 Cr45.01 Cr
Gross Profit -131.92 Cr150.99 Cr197.92 Cr260.76 Cr
Operating Expenses -97.50 Cr111.78 Cr159.99 Cr194.50 Cr
Operating Income -34.43 Cr38.16 Cr37.93 Cr66.25 Cr
EBITDA -44.44 Cr50.95 Cr59.97 Cr93.00 Cr
Interest Expense -81.10 L1.16 Cr9.42 Cr8.31 Cr
Pretax Income -35.99 Cr40.56 Cr31.60 Cr63.02 Cr
Tax Provision -9.30 Cr10.18 Cr10.18 Cr16.29 Cr
Net Income -26.69 Cr30.38 Cr21.43 Cr46.73 Cr
Diluted EPS -1.641.861.312.87

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -181.65 Cr263.72 Cr286.00 Cr332.12 Cr
Current Assets -51.86 Cr33.52 Cr33.24 Cr81.21 Cr
Cash & Equivalents -1.84 Cr4.85 Cr9.19 Cr50.02 Cr
Inventory -2.27 Cr2.05 Cr3.50 Cr3.88 Cr
Receivables -4.37 Cr4.38 Cr5.98 Cr7.35 Cr
Total Liabilities -68.15 Cr120.14 Cr121.67 Cr121.69 Cr
Current Liabilities -22.54 Cr46.45 Cr37.94 Cr42.67 Cr
Long Term Debt -39.87 Cr63.85 Cr72.33 Cr61.43 Cr
Total Debt -49.94 Cr81.82 Cr89.45 Cr83.68 Cr
Total Equity -113.50 Cr143.58 Cr164.33 Cr210.43 Cr
Shares Outstanding -16.31 Cr16.31 Cr16.31 Cr16.31 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -32.33 Cr38.42 Cr57.58 Cr79.10 Cr
Investing Cash Flow --47.99 Cr-55.91 Cr-50.94 Cr-16.93 Cr
Financing Cash Flow -15.84 Cr20.50 Cr-2.30 Cr-21.34 Cr
Capital Expenditure --44.11 Cr-75.27 Cr-63.88 Cr-16.64 Cr
Free Cash Flow --11.79 Cr-36.85 Cr-6.30 Cr62.46 Cr
Net Change in Cash -17.03 L3.01 Cr4.34 Cr40.83 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -85.2%86.1%85.5%85.3%
Operating Margin % -22.2%21.8%16.4%21.7%
Net Margin % -17.2%17.3%9.3%15.3%
ROE % -23.5%21.2%13.0%22.2%
ROCE % -21.6%17.6%15.3%22.9%

Shareholding Pattern

Insiders
77.49%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KMCSHIL

Google News ue, 18 Aug 2026

KMCSHIL Stock Price and Chart — NSE:KMCSHIL - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE5zV1FReUwyZU9hUmVncllXVjR6djJtUzJfUzY5LThpWEJwV0ZDNENwaWk2X0JJV1gyMTdKcTNob3hSRTlKMjBWdVVFdjJkOXdqMm1UVGhtX3paOWxu?oc=5" target="_blank">KMCSHIL Stock Price and Chart — NSE:KMCSHIL…

Google News Wed, 14 Oct 2026

KMC Speciality Hospitals Share Price Today: key numbers - Univest

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPYWMyb0NPemgwc1NmMl9oRHJXSHRIWHJqYlFnd2MtR2duNzhULUh3dEk2d0VNa0I1c29NVVFOUnJEb0Y1TjlpWHRvNXd2b2g2aFpKZ2xfaG5ibzZmdkpXeV8xUEozNGFLZGlTRllkN1IzN1NYTFZBVERsT3RZNWlLMXAtanJ5SXBrUGRMTW…

Google News hu, 01 Oct 2026

KMC Speciality Hospitals Share Price today near yearly high - Univest

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQRXM4cS0yM0lId0kwNlV3cmo2cnByMFBXdWNxY2txdXdIYmZqUjI3Z2Rub2ZwM2hLUGxPV1V3UUpsNVMzaEZYdFlWcUNzcVNTM09rMUJ0cnFxWGFwWElvNE1Nd0JkWVVIWEkyYklLRDRmclhmMG1LSGtnRGZXNGdBSEpXV1lPT0N6ZW9PYU…

Google News Wed, 30 Jul 2025

KMC Speciality Hospitals Share Price Today - KMC Speciality Hospitals (India) Ltd. Stock Price Live NSE/BSE - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9QdkJMRFl3aTkzc0pJN2FCTjZTRGFDN0gwWTAwU2piN2Jud2JkX1FDX18zLWU2QkVOSk43MHliS3hHempxSjdQUVFXeW5FSDItTEtDMjJrUE9RSFI2VDdBZ1oxOEZaR3ZUNzc5SWpR?oc=5" target="_blank">KMC Speciality Hosp…

Google News Mon, 25 May 2026

KMC FY26 net profit jumps 118% to ₹4,673 lakh on revenue growth - scanx.trade

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNb0JRNE1xU0NFUUVWUEtLcklKcmdUcU5KSHM2elhfcTB0Y1BsNzdUeERyVEdpRFNOQTl6Y2MtQ1BfNklpVjZTSEVSb1Qyd2dIRkxGNXBjZjFMamRCZjdwTV9DLXc3SFoxZVlnTEZDWlhuVlVtdWt5Nk9DQnRiakZULXJpWWJSWVhCVVY0SF…

Google News ue, 26 Jun 2018

KMC Speciality Hospitals (India) Limited Trade Ideas — BSE:KMCSHIL - TradingView

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE85bGliaVVSeDAyMUpkS2hCeHhjOEFwUmZrQmlHTm5QalNiNEo4WnhPeUZVS0xaNnJRbnAxT19vTVlWYmR1SHhrbU4yZ0xVNUJiOVFxdHhPMXZ0bTVFYUhMUGJCSXU?oc=5" target="_blank">KMC Speciality Hospitals (India)…

KMCSHIL — Frequently Asked Questions

What is the current share price of KMC Speciality Hospitals (India) Limited (KMCSHIL)?

As of 2026-10-23 04:58 IST, KMC Speciality Hospitals (India) Limited (KMCSHIL) trades at ₹150.05 on NSE. Its 52-week range is ₹132.80 to ₹183.22.

What is the market capitalisation of KMCSHIL?

KMC Speciality Hospitals (India) Limited (KMCSHIL) has a market capitalisation of ₹2,447.09 Cr on NSE.

What is the P/E ratio of KMCSHIL?

KMCSHIL trades at a trailing price-to-earnings (P/E) ratio of 43.62. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 12.07.

What is the return on equity (ROE) of KMCSHIL?

KMCSHIL has a return on equity (ROE) of 22.21%. Its return on capital employed (ROCE) is 22.89%.

Is KMCSHIL a good stock to buy?

This page provides a data-driven analysis of KMC Speciality Hospitals (India) Limited (KMCSHIL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space